Assessing site performance in the Altair study, a multinational clinical trial

Berthon-Jones, Nisha, Courtney-Vega, Kymme, Donaldson, Anna, Haskelberg, Hila, Emery, Sean and Puls, Rebekah (2015) Assessing site performance in the Altair study, a multinational clinical trial. Trials, 16 1: . doi:10.1186/s13063-015-0653-x

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads
UQ511949_OA.pdf Full text (open access) application/pdf 564.24KB 0

Author Berthon-Jones, Nisha
Courtney-Vega, Kymme
Donaldson, Anna
Haskelberg, Hila
Emery, Sean
Puls, Rebekah
Title Assessing site performance in the Altair study, a multinational clinical trial
Journal name Trials   Check publisher's open access policy
ISSN 1745-6215
1468-6708
Publication date 2015-04-01
Year available 2015
Sub-type Article (original research)
DOI 10.1186/s13063-015-0653-x
Open Access Status DOI
Volume 16
Issue 1
Total pages 10
Place of publication London, United Kingdom
Publisher BioMed Central
Language eng
Formatted abstract
Background
Reviewing clinical trial site performance identifies strategies to control outcomes. Performance across 5 geographical regions (36 sites across Asia, Australia, Europe, North America and Latin America) was investigated in a study that randomised 322 HIV-infected individuals.

Methods

Regional performance was compared using descriptive analysis for time to site opening, recruitment, quality of data and laboratory samples. Follow-up consisted of 10 visits (96 weeks), electronic data collection (EDC) within 7 days of a visit and serious adverse events (SAEs) reported within 24 hours of site awareness.

Results
Median days to site opening was 250 (188 to 266), ranging from 177 (158 to 200) (Australia) to 265 (205 to 270) (Europe). Median days to ethics and regulatory approval was 182 (120 to 241) and 218 (182 to 341) days, respectively. Within regions, time to approval ranged from 187 (91 to 205) days (Australia) to 276 (175 to 384) days (Europe). Time to first randomisation ranged from 282 (250 to 313) days (Australia) to 426 (420 to 433) days (North America).

Recruitment was lower than forecasted in Asia, Australia, Europe and North America at 89%, 77%, 91% and 43%, respectively. The converse was true in Latin America where despite ethics, regulatory and contractual delays, recruitment was 104% of predicted.

Median days to EDC was 7 (3 to 16), ranging from 3 (1 to 16) (Asia) to 13 (8 to 14) days (North America). Median days for initial SAE submission to sponsor was 6 (2 to 20), ranging from 4 (2 to 18) (Latin America) to 24 (5 to 46) days (Australia). Sites took longer to submit final reports, overall median of 28 (7 to 91) days, ranging from 7 days (Australia) to 67 (23 to 103) days (Europe).

Conclusions
Population availability and time to ethics and regulatory approvals influence recruitment; therefore accurate feasibility assessments are critical to site selection. Time to ethics and regulatory approval may not limit site inclusion if compensated by rapid recruitment. Identifying potential delays and methods for reduction can decrease time and costs for sponsors.

Trial registration
Clinical Trials.Gov identifier: NCT00335322. Date of registration: 8 June 2006
Keyword Altair
Benchmarking performance
Clinical trial data quality
Clinical trial performance metrics
Clinical trial start-up
Laboratory sample quality in clinical trials
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collection: Faculty of Medicine
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 1 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 1 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Sat, 18 Mar 2017, 01:00:47 EST by Web Cron on behalf of Learning and Research Services (UQ Library)